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Abstract The aim of this study was the preparation of
novel polyester nanoparticles based on folic acid (FA)–
functionalized poly(ethylene glycol)–poly(propylene suc-
cinate) (PEG–PPSu) copolymer and loaded with the new
anticancer drug ixabepilone (IXA). These nanoparticles
may serve as a more selective (targeted) treatment of breast
cancer tumors overexpressing the folate receptor. The
synthesized materials were characterized by 1H-NMR,
FTIR, XRD and DSC. The nanoparticles were prepared by
a double emulsification and solvent evaporation method
and characterized with regard to their morphology by
scanning electron microscopy, drug loading with HPLC–
UV and size by dynamic light scattering. An average size
of 195 nm and satisfactory drug loading efficiency (3.5 %)
were observed. XRD data indicated that IXA was incor-
porated into nanoparticles in amorphous form. The
nanoparticles exhibited sustained drug release properties
in vitro. Based on in vitro cytotoxicity studies, the blank
FA–PEG–PPSu nanoparticles were found to be non-toxic
to the cells. Fluorescent nanoparticles were prepared by
conjugating Rhodanine B to PEG–PPSu, and live cell,
fluorescence, confocal microscopy was applied in order to
demonstrate the ability of FA–PEG–PPSu nanoparticles to
enter into human breast cancer cells expressing the folate
receptor.
Graphical Abstract
1 Introduction
Breast cancer accounts for 22.9 % of all cancers (excluding
non-melanoma skin cancers) in women. Although breast
cancer is less common between men, men tend to have
poorer outcomes due to delays in diagnosis [1]. It is esti-
mated that 1.1 million new cases appear annually, and
about 400.000 related deaths are reported worldwide [2]. A
new effective anticancer drug in the breast cancer treatment
is ixabepilone (IXA), which is the first of a new class of
microtubule-targeting agents called epothilones. It is a
semisynthetic analogue of natural epothilone B that was
rationally designed to have improved metabolic stability
compared with natural epothilone B. In addition to its
favorable pharmacokinetics and metabolic stability, IXA
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displays reduced susceptibility to multidrug-resistance–
mediated efflux and has demonstrated preclinical antitumor
activity in a number of in vivo models of tumors that are
resistant through overexpression of multidrug-resistance
proteins and to taxanes [3, 4].
A major challenge in cancer therapy is the selective
(targeted) delivery of anticancer drugs to the tumor cells,
which would reduce drug toxicity to normal tissues and
cells. While systemic drug delivery already hinges largely
on physicochemical properties of the drug, such as size,
diffusivity, and plasma protein binding affinity, tumors
possess a dense, heterogeneous vasculature and an outward
net convective flow that act as hurdles to efficient drug
deposition at the target site. Nanocarrier mediated delivery
has emerged as a successful strategy to enhance delivery of
therapeutics and imaging agents to tumors, thereby
increasing the potential for diagnosis at an earlier stage or
for therapeutic success (or both). Drug incorporation into
nanoparticulate carriers could provide for a more selective
drug delivery (drug targeting), prolong the biological
activity, protect drug against degradation, and could con-
trol the rate of drug release allowing for the reduction of
drug administration frequency [5].
Biocompatible and biodegradable polymers, such as
poly(lactic acid) (PLA), its copolymers with glycolic acid
(PLGA) and poly(e-caprolactone) (PCL), have been
extensively used to produce nanoparticles for controlled
release and drug targeting applications. Although these
polyesters are widely used as drug carriers and implants,
their low degradation rate [6] sparked an increased interest
for the synthesis of new materials with innovative and
enhanced properties. Poly(propylene succinate) (PPSu) is
such a new biocompatible polyester with relatively high
biodegradation rate due to its low degree of crystallinity [7,
8]. Furthermore, due to its low melting point
(Tm = 44 C), which is close to the physiological body
temperature [9, 10], PPSu could be used as drug nanocar-
rier appropriate for selective drug release at the tumor site
using local hyperthermia. In order to avoid the rapid
removal of these nanoparticles from systemic circulation
after intravenous administration, due to rapid uptake by
reticular endothelial system (RES), pegylated PPSu
nanoparticles based on PEG–PPSu copolymers have been
developed [11–18]. Although pegylation of nanoparticles
surface can lead to their preferential accumulation in tumor
tissue due to the enhanced permeability and retention
(EPR) phenomenon, it does not appear to increase the
uptake of nanoparticles, and consequently of their drug
load, by cancer cells [19]. In order to enhance nanoparticles
uptake by tumor cells, targeting moieties, e.g. antibodies or
antibody fragments, peptides and sugars, specifically rec-
ognized by receptors in cancer cells are attached on
nanoparticles [20].
The aim of the present study is to synthesize tar-
getable PEG–PPSu nanoparticles of ixabepilone by
attaching folic acid (FA) on PEG–PPSu copolymers. FA
can be conjugated to polymers after modification by an
appropriate ‘‘spacer’’ (i.e. –NH2–CH2–CH2–SH–) that
maintain its activity and functionality [5, 18, 21]. The
ixabepilone-loaded FA–PEG–PPSu nanoparticles were
prepared by a modified w/o/w emulsification and solvent
evaporation process and characterized for their physico-
chemical and drug release properties. Furthermore, and in
order to study the uptake of these nanoparticles by cancer
cells using live cell fluorescence microscopy, fluorescent
Rhodamine was covalently attached to PEG–PPSu used to
prepare the nanoparticles.
2 Materials and methods
2.1 Materials
For the synthesis of conjugated polyester succinic acid
(purum 99 %), 1,3-propanediol (purum 99 %), tetrabutyl
titanate (TBT), tripolyphenylphosphine (Ph3P), diethyl
azodicarboxylate (DEAD), poly(ethylene glycol) (PEG)
with molecular weight 2000, maleimide (MAL) and
Sn(octanoate) were use purchased from Aldrich Chemical
Co. N-hydroxysuccinimide (NHS), triethylamine (TEA)
and dicyclohexylcarbodiimide (DCC) were also purchased
from Aldrich Chemical Co. Ixabepilone drug was pur-
chased from BOC Sciences. All the other reagents were of
analytical grade.
2.2 Synthesis of functional polyesters
2.2.1 Functionalization of PEG with maleimide (MAL–
PEG) and conjugation of MAL–PEG into PPSu
(MAL–PEG–PPSu) (Scheme 1)
For the preparation of MAL–PEG a 250 mL round bottom
flask was charged with Ph3P (2.70 g, 10.3 mmol) to which
70 mL of THF were added. The resulting clear solution
was cooled to -78 C. DEAD (1.63 mL, 10.3 mmol) was
added over 2–3 min. The yellow reaction mixture was
stirred 5 min and then PEG (1.36 mL, 11.3 mmol) was
added over 1 min and stirred for 5 min. Neopentyl alcohol
(0.50 g, 5.7 mmol) and MAL (1.00 g, 10.3 mmol) were
added sequentially to the reaction mixture as solids. The
resulting suspension was allowed to remain at -78 C for
5 min during which time most of the MAL dissolved. The
cooling bath was then removed, and the reaction was
stirred overnight at ambient temperature. Thin layer chro-
matography (TLC) indicated complete consumption of
MAL. The clear solution was concentrated to
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approximately  of the original volume under vacuum and
then it was applied to a silica gel column (2 in 9 8 in) and
eluted with 5:l hexanol/EtOAc to obtain MAL–PEG
(Scheme 1), after removing solvent.
For the preparation of MAL–PEG–PPSu the synthesis of
PPSu was performed following a two stage melt polycon-
densation method (esterification and polycondensation) in
a glass batch reactor according to the method described in
our previous study [5].
A pre-determined amount of MAL–PEG–OH, PPSu and
Sn(Oct)2 catalyst (0.1 % amount of polyester in molar
ratio) was dissolved in dry toluene in a flame-dried two-
neck flask equipped with a distillation set. The mixture was
heated to 130 C and refluxed for 5 h. Subsequently, the
solution was cooled to room temperature and precipitated
into cold diethyl ether. The product (MAL–PEG–PPSu)
(Scheme 1) was collected by filtration and dried in vacuum
at room temperature.
2.2.2 Conjugation of folic acid onto MAL–PEG–PPSu
(FA–PEG–PPSu) (Scheme 2)
For the synthesis of FA–PEG–PPSu, the folic acid should
first be activated as folate-NHS ester (Scheme 2a). The
carboxylate group of FA was activated by N-hydroxysuc-
cinimide (NHS) and dicyclohexylcarbodiimide (DCC).
Briefly, 1 g FA was dissolved in 50 mL dimethyl sulfoxide
(DMSO). Then, NHS and DCC in a stoichiometric ratio of
FA: NHS: DCC 1:2:1 were added to the solution. The
solution was stirred 16 h at room temperature under
shielding from light. The by-product dicyclohexylurea was
removed by filtration. The supernatant was added in glacial
diethylether and the solid formed was filtrated and dried for
3 days at 30 C. The dried product was dissolved in DMSO
and cysteamine- hydrocloride and 0.1 mL (TEA) were
added. Subsequently, the solution was stirred for 24 h and
the final product was recovered after pouring into diethy-
lether. The modified-folic acid (FA-NHS) was washed
thrice with purified water and dried at 30 C.
In the second step (Scheme 2b), activated FA reacted
with MAL–PEG–PPSu. Briefly, 10 mg of FA–NHS were
added in 20 lL of TEA and a proper amount of MAL–
PEG–PPSu was dissolved in 10 mL of DMSO. The solu-
tions were mixed and stirred for 24 h at room temperature.
DMSO residue was removed via distillation in order to
receive a yellow colored polymer.
2.2.3 Conjugation of Rhodamine B to PEG–PPSu
(Scheme 3a, b)
In order to be able to observe the entry of the nanopar-
ticles into cancer cells with fluorescence microscopy,
functionalized with the fluorescent dye Rhodamine B (Rh)
PEG–PPSu was synthesized, which was then used to
prepare fluorescent nanoparticles. The Rh conjugated
PEG–PPSu was synthesized according to a published
work [22]. Briefly, activation of Rh was effected when
0.1 gr of Rh was added into 10 mL DMSO and 0.06 mL
TEA. After dissolving the dye, 51.6 mg of DCC and NHS
were added. Magnetic stirring in the dark was continued
for 24 h and the dicyclohexylurea produced was removed
by filtration. DMSO and TEA were evaporated under
Scheme 1 Schematic
representation of
functionalization of PEG with
Maleimide (MAL–PEG) and
synthesis of MAL–PEG–PPSu
during reaction of MAL–PEG
with PPSu polyester
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vacuum and the activated Rh-NHS (Scheme 3a) was dried
under vacuum.
The dried Rh–NHS dissolved in 10 mL DMSO where
0.4 g of the PEG–PPSu and 0.02 mL TEA were also added
in proportional amounts. The solution was stirred overnight
and then dialyzed for 2 days. The final product was col-
lected by lyophilization (Scheme 3b).
2.3 Functional materials characterization
2.3.1 Wide angle X-ray diffraction
Wide Angle X-ray diffraction (WAXD) measurements of
the samples were performed by an automated powder
diffractometer Rigaku Mini Flex II with Bragg–Brentano
(a)
(b)
Scheme 2 a Schematic
diagram of a production of
activated folic acid (NHS-ester
of FA) and b folic acid
conjugation on PEG–PPSu to
obtain FA–PEG–PPSu
275 Page 4 of 14 J Mater Sci: Mater Med (2015) 26:275
123
geometry (h–2h), using CuKa radiation (k = 0.154 nm) in
the angle 2h range from 5 to 50.
2.3.2 Fourier-transform infrared spectroscopy
FTIR spectra of the samples were taken with a FTIR–
spectrometer (model FTIR–2000, Perkin Elmer, Dresden,
Germany) using KBr disks (thickness of 500 lm). The
spectra were recorded from 4000 to 400 cm-1 at a reso-
lution of 2 cm-1 (64 co–added scans).
2.3.3 1H-NMR spectroscopy
1H-NMR spectra of polyesters were obtained with a Bruker
spectrometer operating at a frequency of 400 MHz for
protons. Deuterated chloroform (CDCl3) was used as sol-
vent in order to prepare solutions of 5 % w/v. The number
of scans was 10 and the sweep width was 6 kHz.
2.3.4 Differential scanning calorimetry
Differential scanning calorimetry (DSC) was performed on a
Perkin–Elmer, Pyris Diamond differential scanning
calorimeter. A Perkin Elmer Intracooler 2P cooling accessory
was used. Samples of 5.0 ± 0.1 mg were sealed in aluminium
pans and heated above the melting point of polyesters under
nitrogen atmosphere at a heating rate 10 C/min.
2.4 Preparation of IXA loaded polyester
nanoparticles
IXA nanoencapsulation was carried out with a modified
water–oil–water (w/o/w) emulsification/solvent evapora-
tion method. In brief, 5 mg IXA were dissolved in 0.5 mL
mixture of water with methanol (35:65 v/v) and the solu-
tion was emulsified with probe sonication at 15 W for
2 min in a FA–PEG–PPSu–FA solution in dichlor-
omethane, typically 50 mg (45 mg of FA–PEG–PPSu—
5 mg Rh–PEG–PPSu) polymer in 3 mL solvent. This
emulsion was transferred to an aqueous solution of PVA
(V = 9 mL, 0.66 % w/v PVA) and the mixture was probe
sonicated for 1 min. The formed w/o/w emulsion was
gently stirred at room temperature and organic solvents
were allowed to be evaporated completely. The nanopar-
ticles were purified by centrifugation (9500 rpm for
20 min). The samples were reconstituted with deionized
(a)
(b)
Scheme 3 Schematic diagram
of a Rhodamine’s activation and
b conjugation of activated
Rhodamine to PEG–PPSu
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water. The suspension was filtered by a microfilter with
pore size of 1.2 lm in order to remove polymer aggregates
possibly formed.
2.5 Characterization of drug loaded nanoparticles
2.5.1 Nanoparticle yield, drug loading and entrapment
efficiency
For the determination of the drug loading content, 3 mg of
freeze-dried nanoparticles were dissolved in 50 lL MeOH
and diluted to 40 mL ACN/10 mM ammonium acetate 70/
30 (v/v). The concentration of IXA in this solution was
measured by High Performance Liquid Chromatography
system using a Shimadzu HPLC (model LC-20AD) system.
The column used was a CNW Technologies Athena C18,
120 A, 5 lm, 250 mm 9 4.6 mm with column temperature
of 25 C. The mobile phase consisted of ACN/10 mM
ammonium acetate 70/30 (v/v) at a flow rate of 0.5 mL/
min. Concentration determination was performed using an
UV detector at 254 nm and was based on a previously
created calibration curve. Nanoparticle yield, drug loading
and drug entrapment efficiency were calculated using
Eqs. (1)–(3), respectively:
Nanoparticles yield ð%Þ
¼ Weight of nanoparticles
Weight of polymer and drug fed initially
 100 ð1Þ
Drug loading content ð%Þ
¼ Weight of drug in nanoparticles
Weight of nanoparticles
 100 ð2Þ
Entrapment efficiency ð%Þ
¼ Weight of drug in nanoparticles
Weight of drug fed initially
 100 ð3Þ
2.5.2 Morphology
The morphology of the prepared nanoparticles was exam-
ined with a Scanning Electron Microscope (JEOL, JMS–
840). The samples were coated with carbon black to avoid
charging under the electron beam. Operating conditions
were: accelerating voltage 20 kV, probe current 45 nA, and
counting time 60 s.
2.5.3 Particle size distribution by dynamic light scattering
(DLS)
Particle size distribution of the IXA/polyester nanoparticles
was determined by dynamic light scattering (DLS) using a
Zetasizer Nano instrument (Malvern Instruments, Nano ZS,
ZEN3600, UK) operating with a 532 nm laser. A
suitable amount of nanoparticles was dispersed in distilled
water creating a total concentration 1 % and was kept under
agitation at 37 C in a water bath. Particle size was measured
at different time intervals after sample introduction into the
dispersion medium. All measurements were performed in
triplicates and the results were reported as mean diame-
ter ± SD (standard deviation).
2.6 In vitro drug release
For the in vitro release studies, a dissolution apparatus type
DISTEK 2100B equipped with an autosampler using the
paddle method (USP II method) was used. Each dissolution
vessel was loaded with quantity of nanoparticles corre-
sponding to 2 mg of IXA. The test was performed at
37 ± 1 C with a rotation speed of 100 rpm. The disso-
lution medium was 500 mL of a solution simulating the
inorganic composition of the body fluids (SBF) prepared
according the Kokubo and Takadama procedure [23]. At
predetermined time intervals, samples of 2 mL were
withdrawn from the dissolution medium, filtered through
45 lm UHMW polyethylene filters and assayed using an
HPLC–UV method for the drug at 254 nm. In order to
investigate the release mechanism, the obtained release
data were fitted to several release models, such as zero
order, first order, Hixson Crowell, Higushi and Korsmeyer-
Peppas.
2.7 In vitro cytotoxicity studies: cells and culture
conditions
HeLa Kyoto (HeLa K) and MCF7 cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % FBS, 2 mM L-glutamine, 100 U/mL
penicillin and 100 lg/mL streptomycin (Invitrogen), at
37 C with 5 % CO2 in a humidified incubator. Cell number
was determined in duplicates using a haemocytometer. HeLa
Kyoto and MCF7 cells were seeded in flat-bottomed 96-well
plates (Sigma-Aldrich) at a density of 5000 and 8500 viable
cells per well, respectively. Cells were incubated for 24 h to
allow cell attachment. Cells were further incubated for 48 h
with either PPSu–PEG or FA–PPSu–PEG nanoparticles at
polymer concentrations ranging from 0.02 to 10 lg/mL.
After 48 h, a cell proliferation assay was performed: cells
were washed twice with 1x PBS followed by an additional
1-h incubation with 100 lL of DMEM containing 10 lL/
well Premix WST-1 (Takara). Absorbance of the formazan
product was measured at 440 nm using a microplate plate
reader (Infinite M1000, Tecan), while the reference wave-
length was measured at 660 nm. Untreated cells were used as
control for 100 % viability, and wells with only the culture
medium and the Premix were used as background control
(blank).
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2.8 Live cell microscopy
For live cell microscopy, 3 9 104 HeLa Kyoto cells were
placed on Lab-Tek glass bottomed dishes 1 day before
utilisation, and imaged on a customized Andor Revolution
Spinning Disk Confocal System built around a stand (IX81;
Olympus) with a 920 air objective and a digital camera
(Andor Ixon ? 885) (CIBIT Facility, MBG-DUTH)
equipped with an incubator at 37 C. Prior to imaging, cells
were washed twice with a CO2-independent medium, (041-
95374, Life technologies) supplemented with 10 % FBS,
1 % L-Glu, 100 U/mL penicillin and 100 lg/mL strepto-
mycin, and then incubated in the same medium for imag-
ing. Hoechst 33,342 at 1 lg/mL final concentration was
used to visualise the cell nucleus. Rhodamine was cova-
lently attached to the nanoparticles in order to visualize
them. Images were acquired as z stacks, according to
experimental needs. Autofocus was performed at each time
point before capturing a z-stack to ensure that the entire
cell was captured. Image acquisition was performed in
Andor IQ 2 software. Optical sections were recorded every
0.3 lM. Image intensity analysis for data sets were per-
formed in ImageJ 1.44n (National Institute of Health, USA)
software. All microscopy images presented here are 2D
maximum intensity projections of z-stack images (ImageJ
1.44n National Institute of Health, USA).
3 Results and discussion
3.1 Chemical structure and characterization
of functional materials
For the characterization of the synthesized materials and
mainly to see if the proposed reactions are taking place 1H-
NMR and FTIR spectroscopies were used and the recorded
spectra of all materials are presented in Figs. 1 and 2,
respectively. According to our previous study [9], the 1H-
NMR spectrum of neat PPSu presents a single peak at
2.63 ppm which is attributed to the a (Fig. 1) methylene
protons of succinic acid, a multiple peak between 1.9 and
2.02 ppm corresponding to the d (See Fig. 1) protons of
propanediol and a triple peak at 4.09-4.21 ppm attributed to
the c (Fig. 1) protons (–CH2–O–) of propanediol. The
1H-
NMR spectrum of MAL–PEG–PPSu copolymer in addition
exhibits a peak at 3.6 ppm assigned to the methylene groups
of PEG and a peak at 4.18–4.3 ppm ascribed to the methy-
lene groups of ethyleneglycol [21]. FA–PEG–PPSu
copolymer presents, in addition to the above mentioned
peaks, two small peaks at 7.8 and 8.0 ppm (See Fig. 1 and
inset in Fig. 1) assigned to protons of FA [24].
Respectively, in FTIR spectrum (Fig. 2) of neat PPSu,
a strong band at 1734–735 cm-1 of carbonyl groups
C=O and a broad band at 3433–3439 cm-1 assigned to –
OH groups can be observed. Furthermore, some other
peaks at 1454–1474 cm-1 (–CH–) and at
1163–1167 cm-1 (C–O–C stretching) can be also seen
[25]. MAL–PEG–PPSu spectrum includes the following
peaks: the strong band at 1726 cm-1 assigned to the
carbonyl groups of polyester and a broad band at
3500–3400 cm-1 corresponds to the hydroxyl groups of
PEG conjugated to the polymer. Three small peaks that
recorded at 1608, 1686 and a 606 cm-1 in FA–PEG–
PPSu copolymer indicated the conjugation of modified
FA into PEG–PPSu since these two peaks existed only in
the neat modified FA [26]. Evidence of the existence of
hydrogen bonding between FA and PEG provides the
shifting in lower wavenumber of band at 1608 cm-1.
FTIR spectroscopy as well as 1H-NMR confirm the
successful preparation of the modified PPSu copolymers
containing PEG and FA groups.
The successful conjugation of activated Rhodamine to
PEG–PPSu was shown using FTIR spectroscopy. In
Fig. 2b the spectrum of Rhodamine B is presented. At
2967 cm-1 the peak of the methylene groups of aromatic
rings is observed while at 1766 cm-1 the absorbance of the
carbonyl group is recorded. The shifting of the peak at
1731 cm-1 in the spectrum of Rh–MAL–PEG–PPsu
material and the existence of a small peak at 1623 cm-1
(C=N stretching) indicate the successful conjugation of
Rhodamine on the polymeric carrier.
9 8 7 6 5 4 3 2 1 0
FA-PEG-PPSu
MAL-PEG-PPSu
PPSu
O-CH2-CH2-CH2-O-C-CH2-CH2-C
O O
cc d
n
789
ppm
FA-SH
ppm
a dc
PPSu structure
a a
Fig. 1 1H-NMR spectra of PPSu, MAL–PEG–PPSu and FA–PEG–
PPSu
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The physical state of the synthesized functionalized
PPSu copolymers has also been studied with XRD and
DSC, since it is well known that crystallinity plays an
important role in drug release from polymeric systems [27].
PPSu is a semicrystalline polyester with low melting point
close to the human body temperature. In Fig. 3, the XRD
patterns of neat PPSu, FA–PPSu, MAL–PEG–PPSu and
FA–PEG–PPSu are illustrated. Meat PPSu presents char-
acteristic crystalline peaks at 2h = 19.6, 22.49, 25.92
and 34.45. FA exhibits also weak peaks at 16, 35 and
42, confirming its crystalline nature. MAL–PEG–PPSu
displays 4 main crystalline peaks at 19, 21, 22 and 27.
These peaks appeared also in the diffractogram of
FA–PEG–PPSu, too. However, in MAL–PEG–PPSu pat-
tern there is also a small peak, which was recorded as
shoulder, at 20.92, corresponded to the addition of PEG
into PPSu. After the addition of FA into MAL–PEG–PPSu,
a more amorphous material was prepared (FA–PEG–
PPSu), since the peaks of PPSu are not so clearly visible. It
appears that the addition of PEG and FA in PPSu chains
modified its crystalline structure and copolymers with
lower crystallinity were obtained.
Differential scanning calorimetry (DSC) was also used
to investigate the physical structure of synthesized mate-
rials (See Fig. 4). Neat PPSu exhibited a melting point at
49 C and a Tg value at -27.6 C, in accordance to our
previous work [8]. The addition of MAL–PEG into PPSu
reduced the melting point of PPSu to 35.6 C due to co-
crystallization with PEG, as was verified by the XRD
studies, while a second melting point appeared at 47.4 C.
The co-crystallization structural consequences became
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A
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Fig. 2 FTIR spectra of a PPSu, modified FA, MAL–PEG–PPSu and
FA–PEG–PPSu and b Rhodamine-B and Rh–PEG–PPSu
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Fig. 3 X-ray diffraction (XRD) patterns of FA–NHS (FA modified),
PPSu-neat, MAL–PEG–PPSu and FA–PEG–PPSu
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Fig. 4 Differential scanning calorimetry thermograms (DSC) of
PPSu, MAL–PEG–PPSu, and FA–PEG–PPSu
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more clearly evident in the Tg value, which is shifted to
-37.3 C due to the plasticization effect of PEG, since neat
PEG has a Tg value near to -60 C. The heat capacity at
Tg area in MAL–PEG–PPSu sample has been increased
while the heat of fusion of melting point has been reduced,
compared with neat PPSu, which is an indication that
MAL–PEG–PPSu is more amorphous than PPSu. The Tg
temperature of FA–PEG–PPSu appeared at -37.1 C,
almost identical to that of MAL–PEG–PPSu. Two meting
points were also recorded at 37.8 and 48.5 C, but the
respective peaks were smaller than those corresponding to
MAL–PEG–PPSu. This confirms that FA–PEG–PPSu is
more amorphous than neat PPSu and its MAL–PEG–PPSu
copolymer, in accordance to the XRD results (See Fig. 3).
3.2 Characterization of functionalized nanoparticles
The FA-modified copolymers were used to prepare IXA-
loaded nanoparticles. The prepared nanoparticles were
initially characterized using SEM and Fig. 5 presents SEM
micrograph of FA–PEG–PPSu nanoparticles of IXA. It is
clear that individual particles with spherical shape were
obtained. Dynamic light scattering (DLS) was used to
characterize the size characteristics of the nanoparticles.
Size is important for efficient tumor localization of
nanoparticles after intravenous administration, with
nanoparticles with size in the range of 20–200 nm accu-
mulating preferentially at tumors due to the EPR phe-
nomenon [20, 21]. According to DLS measurements (See
Fig. 6), the size of nanoparticles ranged between 40 and
700 nm, with a mean particle size of 195 nm while the
majority of the NPS present the favorable size of
100–200 nm. Therefore, we can suggest the folate-NPS are
suitable for their potential use as targetable nanocarriers of
IXA [28–30]. In the literature, the definition of nanoparti-
cles is not clear. However, according to several works, the
researchers define NPs even they have 500 or 700 nm size
[31].
Drug loading in nanoparticles can be affected by various
factors, such as polymer molecular weight, crystallinity
and ratio of hydrophilic segments in the macromolecular
chains [22]. Table 1 summarizes the nanoparticle yield,
drug loading and entrapment efficiency of FA–PEG–PPSu
nanoparticles. Satisfactory IVA (%) loading and entrap-
ment efficiency were obtained with the modified w/o/w
emulsification and solvent evaporation technique applied to
prepare the nanoparticles.
In order to reveal if there any interactions between IXA
(Fig. 7a) and polymer matrix, all prepared nanoparticles
were studied by FTIR spectroscopy and were compared
with IXA and the Folate-polymer spectra. As it can be seen
in Fig. 7b, the characteristic peaks of IXA are recorded at
3400 and 2982 cm-1 corresponding to its hydroxyl group
and the secondary amino group, respectively. The spectrum
of nanoparticles loaded with IXA is similar to that of
unloaded FA–PEG–PPSu nanoparticles. So, it can be
argued that there are no interactions between drug and
polymer carrier.
X-Ray diffraction studies were performed in order to
study the physical form of the drug in the prepared
nanoparticles (Fig. 8). The diffractogramm of neat IXA
exhibits some sharp diffraction peaks, with the most
characteristic of them appearing at 15–25. As it was
mentioned above, FA–PEG–PPSu presents a broad peak,
indicating a mainly amorphous structure of the synthesized
Fig. 5 SEM photograph of IXA-loaded FA–PEG–PPSu
nanoparticles
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Fig. 6 Particle size distribution of IXA-loaded FA–PEG–PPSu
nanoparticles based on DLS
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material. In the case of loaded nanoparticles with IXA, the
diffractogamm is similar to that of blank nanoparticles.
However, the characteristic peaks of neat IXA were not
recorded, indicating the dispersion of IXA in amorphous
form inside the nanoparticles.
3.3 In vitro drug release
The drug release from nanoparticulate systems consisting
of biodegradable polymers can be influenced by different
parameters, such as crystallinity, glass transition tempera-
ture, melting point, molecular weight, drug entrapment
efficiency to the polymer, nanoparticles’ size and drug’s
hydrophilicity [23, 32–34]. In Fig. 9, the in vitro release
profiles of non-encapsulated IXA and IXA-loaded
nanoparticles are shown. IXA is poorly soluble drug
according to the literature [35]. About 10 % percentage of
free IXA had been dissolved during the first 5 h. Then,
very slow dissolution was observed indicating the inability
of the chosen model drug to fully be dissolved in body
Table 1 Nanoparticle yield, drug loading and entrapment efficiency of IXA-loaded FA–PEG–PPSu nanoparticles
Nanoparticle yield (%) Drug loading (%) Entrapment efficiency (%)
IXA loaded FA–PEG–PPSu 39.09 3.53 38.80
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Fig. 7 a Structure of ixabepilone and b FTIR spectra of IXA, IXA-
loaded FA–PEG–PPSu nanoparticles, and FA–PEG–PPSu
nanoparticles
5 10 15 20 25 30 35 40 45
FA-PEG-PPSu
FA-PEG-PPSu(IXA)
IXA
In
te
ns
ity
 (c
ou
nt
s)
2theta (degree)
Fig. 8 XRD diffractogram of FA–PEG–PPSu nanoparticles, IVA-
loaded FA–PEG–PPSu nanoparticles and IXA
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Fig. 9 Release profile of neat IXA and IXA encapsulated in FA–
PEG–PPSu nanoparticles
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fluids. However, the initial, relatively fast dissolution could
be attributed to the rapid dissolution of IXA particles with
very small diameter. As far of our knowledge, there are no
reports studying NPs loaded with IXA, consisting of
biodegradable polymer such as PPSu, PLA or PCL. How-
ever, PPSu attached to hydrophilic segments of PEG has
been studied for several model drugs [17]. Vassiliou et al.,
showed that when a hydrophobic drug is entrapped in such
polyesters higher release rates are verified as well as that
the hydrophobic drug was mainly entrapped in hydropho-
bic segments [17]. Taxol a known anti-cancer drug was
successfully encapsulated in magnetic core–shell NPs of
PPsu in which case observed a biphasic pattern- a high
release rate followed by slow dissolution [36]. In our case
of nanoparticles, a biphasic pattern can also be identified.
This behaviour is similar for polymeric nanoparticles [27,
33]. The burst release of around 35 % of IXA content was
observed during the first 2 h, which was followed by a
sustained release. Burst release phenomenon according to
the literature does not have a clear mechanism however can
be controlled by the manufacturing procedure [37]. The
initial fast release from the nanoparticles could be attrib-
uted to the rapid dissolution of drug located on/close to
nanoparticles’ surface [38, 39]. The higher dissolution rate
of encapsulated IXA compared to free (crystalline) IXA
can be attributed to the mainly amorphous state of IXA
entrapped into the polymeric matrix, as indicated by XRD
studies (See Fig. 8). IXA is mainly encapsulated in the
amorphous form in the nanoparticles and it is well known
that amorphous drugs have higher solubility compared with
their crystalline counterparts [33].
The in vitro release profile of IXA from the FA–PEG–
PPSu nanoparticles was analyzed by various kinetic mod-
els. The kinetic models used were zero order, first order,
Higuchi and Korsemeyer-Peppas equation [37]. Release
kinetics was found to fit the Higuchi model best (See
Fig. 10) and thus the release mechanism may be considered
to be drug diffusion.
Additionally, in the prepared NPs it is believed that a
high content of the drug is located near the hydrophilic part
of FA–PEG. After these early stages, the drug from the
hydrophobic part is diffused from the hydrophobic part
indicating the slower release.
3.4 In vitro cytotoxicity and cellular uptake studies
The human cervical cancer cell line HeLa Kyoto (HeLa K)
and the human breast cancer cell line MCF7 were used to
test the cytotoxicity of PPSu–PEG and FA–PPSu–PEG
nanoparticles (NPs) without IXA. The NPs were weighed,
suspended in PBS and added in HeLa K and MCF7 cells.
Figure 11a shows the viability of HeLa K and MCF7 cells
after 48 h of cell culture with either PPSu–PEG or FA–
PPSu–PEG in polymer concentration ranging from 0.02 to
10 lg/mL. No significant cytotoxic activity was found for
the drug-free NPs at all tested concentrations. Moreover,
the addition of folic acid (FA) on the polymer molecules
did not significantly affect cell viability, since
97.2 % ± 0.06 % of HeLa K cells and 87.73 % ± 0.01 %
of MCF7 cells remained viable after 48 h of incubation
with the nanoparticles. As a conclusion, the two different
NPs tested in the two cancer cell lines did not result to
significant loss of cell viability and thus can be considered
to be safe and non-toxic.
In order to confirm the cellular uptake of the FA–PPSu–
PEG nanoparticles after being modified by the tumor cell-
specific targeting ligand folic acid, HeLa cells cell were
used, which are folic acid receptor positive. In order to
visualize the nanoparticles, Rhodamine (Rho) was cova-
lently attached to them and HeLa cells were incubated in
the presence of PPSu–PEG–Rho nanoparticles and their
cell entry was imaged live using a confocal microscope
(See Fig. 11b). Cell entry started at early time points,
achieving a maximum at 5 h. The results confirm the
ability of FA–PPSu–PEG nanoparticles to enter folic-acid
receptor positive cells (HeLa).
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Fig. 10 Fitting the release profile obtained with the nanoparticles to
Higuchi release model
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Fig. 11 a Viability of HeLa K and MCF7 cells after 48 h incubation
with PPSu–PEG and FA–PPSu–PEG nanoparticles. Graphs are the
mean of 3 independent experiments ± SD. b Representative image
showing the cellular uptake of the FA–PPSu–PEG–Rho nanoparticles
in HeLa Kyoto cells, 5 h after their addition to the cell medium. Cell
nuclei were stained with Hoechst 33,342
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4 Conclusion
A novel FA-functionalized PEG–PPSu copolymer was
successfully synthesized and fully characterized. In vitro
cytotoxicity studies indicated that FA–PEG–PPSu is a
cytocompatible material that could safely be used for the
development of targetable nanoparticulate drug carriers.
IXA-loaded nanoparticles of FA–PEG–PPSu, were pre-
pared in a satisfactory yield and with a satisfactory IXA
loading efficiency. The nanoparticles exhibited sustained
drug release profile in simulating body fluid. Moreover, the
nanoparticles were able to enter human breast cancer cells
that express the FA receptor. The results obtained justify
further investigation of the suitability of these nanoparti-
cles to be utilized as targetable IXA nanocarriers in breast
cancer chemotherapy.
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